1. Home
  2. EPSM vs BEAT Comparison

EPSM vs BEAT Comparison

Compare EPSM & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EPSM

Epsium Enterprise Limited Ordinary Shares

N/A

Current Price

$1.35

Market Cap

51.6M

Sector

N/A

ML Signal

N/A

Logo Heartbeam Inc.

BEAT

Heartbeam Inc.

HOLD

Current Price

$1.11

Market Cap

44.8M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
EPSM
BEAT
Founded
2010
2015
Country
China
United States
Employees
N/A
16
Industry
Retail: Computer Software & Peripheral Equipment
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
51.6M
44.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
EPSM
BEAT
Price
$1.35
$1.11
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$6.17
AVG Volume (30 Days)
275.6K
859.5K
Earning Date
12-05-2025
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$260.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.04
$0.54
52 Week High
$155.00
$4.00

Technical Indicators

Market Signals
Indicator
EPSM
BEAT
Relative Strength Index (RSI) 38.78 36.67
Support Level $1.31 $0.91
Resistance Level $2.35 $1.35
Average True Range (ATR) 0.20 0.09
MACD -0.03 -0.01
Stochastic Oscillator 2.35 8.24

Price Performance

Historical Comparison
EPSM
BEAT

About EPSM Epsium Enterprise Limited Ordinary Shares

Epsium Enterprise Ltd is a holding company and conducts business through its subsidiaries. It is engaged in import trading and wholesale selling of beverages in Macau. The company imports and sells a range of beverages, alcoholic beverages, and a small quantity of tea and fruit juice. The alcoholic beverages it sells include Chinese liquor, French cognac, Scottish whiskey, fine wine, Champagne, and other miscellaneous beverage alcohol.

About BEAT Heartbeam Inc.

HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.

Share on Social Networks: